Literature DB >> 25770243

Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy.

Liselotte B Christiansen1, Flemming Dela2, Jørgen Koch3, Christina N Hansen2, Pall S Leifsson4, Takashi Yokota5.   

Abstract

Mitochondrial dysfunction and oxidative stress are important players in the development of various cardiovascular diseases, but their roles in hypertrophic cardiomyopathy (HCM) remain unknown. We examined whether mitochondrial oxidative phosphorylation (OXPHOS) capacity was impaired with enhanced mitochondrial oxidative stress in HCM. Cardiac and skeletal muscles were obtained from 9 domestic cats with spontaneously occurring HCM with preserved left ventricular systolic function and from 15 age-matched control cats. Mitochondrial OXPHOS capacities with nonfatty acid and fatty acid substrates in permeabilized fibers and isolated mitochondria were assessed using high-resolution respirometry. ROS release originating from isolated mitochondria was assessed by spectrofluorometry. Thiobarbituric acid-reactive substances were also measured as a marker of oxidative damage. Mitochondrial ADP-stimulated state 3 respiration with complex I-linked nonfatty acid substrates and with fatty acid substrates, respectively, was significantly lower in the hearts of HCM cats compared with control cats. Mitochondrial ROS release during state 3 with complex I-linked substrates and thiobarbituric acid-reactive substances in the heart were significantly increased in cats with HCM. In contrast, there were no significant differences in mitochondrial OXPHOS capacity, mitochondrial ROS release, and oxidative damage in skeletal muscle between groups. Mitochondrial OXPHOS capacity with both nonfatty acid substrates and fatty acid substrates was impaired with increased mitochondrial ROS release in the feline HCM heart. These findings provide new insights into the pathophysiology of HCM and support the hypothesis that restoration of the redox state in the mitochondria is beneficial in the treatment of HCM.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  hypertrophic cardiomyopathy; mitochondria; oxidative stress

Mesh:

Year:  2015        PMID: 25770243     DOI: 10.1152/ajpheart.00727.2014

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  16 in total

1.  Pre-ischaemic mitochondrial substrate constraint by inhibition of malate-aspartate shuttle preserves mitochondrial function after ischaemia-reperfusion.

Authors:  Nichlas Riise Jespersen; Takashi Yokota; Nicolaj Brejnholt Støttrup; Andreas Bergdahl; Kim Bolther Paelestik; Jonas Agerlund Povlsen; Flemming Dela; Hans Erik Bøtker
Journal:  J Physiol       Date:  2017-02-27       Impact factor: 5.182

2.  Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits.

Authors:  Paul J M Wijnker; Vasco Sequeira; Diederik W D Kuster; Jolanda van der Velden
Journal:  Antioxid Redox Signal       Date:  2018-04-11       Impact factor: 8.401

3.  Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats.

Authors:  Jacob Marthinsen Seefeldt; Thomas Ravn Lassen; Marie Vognstoft Hjortbak; Nichlas Riise Jespersen; Frederikke Kvist; Jakob Hansen; Hans Erik Bøtker
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

4.  Distinct genes and pathways associated with transcriptome differences in early cardiac development between fast- and slow-growing broilers.

Authors:  Jibin Zhang; Carl J Schmidt; Susan J Lamont
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

5.  Linoleic acid improves assembly of the CII subunit and CIII2/CIV complex of the mitochondrial oxidative phosphorylation system in heart failure.

Authors:  Satoshi Maekawa; Shingo Takada; Hideo Nambu; Takaaki Furihata; Naoya Kakutani; Daiki Setoyama; Yasushi Ueyanagi; Dongchon Kang; Hisataka Sabe; Shintaro Kinugawa
Journal:  Cell Commun Signal       Date:  2019-10-16       Impact factor: 5.712

Review 6.  Imbalance of ER and Mitochondria Interactions: Prelude to Cardiac Ageing and Disease?

Authors:  Jin Li; Deli Zhang; Bianca J J M Brundel; Marit Wiersma
Journal:  Cells       Date:  2019-12-12       Impact factor: 6.600

7.  Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Anders Hostrup Larsen; Henrik Wiggers; Ole Lindgård Dollerup; Nichlas Riise Jespersen; Nils Henrik Hansson; Jørgen Frøkiær; Kim Brøsen; Helene Nørrelund; Hans Erik Bøtker; Niels Møller; Niels Jessen
Journal:  Cardiovasc Drugs Ther       Date:  2020-08-08       Impact factor: 3.727

8.  A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model.

Authors:  Fang Wang; Jeremy Travins; Zhizhong Lin; Yaguang Si; Yue Chen; Josh Powe; Stuart Murray; Dongwei Zhu; Erin Artin; Stefan Gross; Stephanie Santiago; Mya Steadman; Andrew Kernytsky; Kimberly Straley; Chenming Lu; Ana Pop; Eduard A Struys; Erwin E W Jansen; Gajja S Salomons; Muriel D David; Cyril Quivoron; Virginie Penard-Lacronique; Karen S Regan; Wei Liu; Lenny Dang; Hua Yang; Lee Silverman; Samuel Agresta; Marion Dorsch; Scott Biller; Katharine Yen; Yong Cang; Shin-San Michael Su; Shengfang Jin
Journal:  J Inherit Metab Dis       Date:  2016-07-28       Impact factor: 4.982

9.  Mitochondrial respiration of complex II is not lower than that of complex I in mouse skeletal muscle.

Authors:  Satoshi Maekawa; Shingo Takada; Takaaki Furihata; Arata Fukushima; Takashi Yokota; Shintaro Kinugawa
Journal:  Biochem Biophys Rep       Date:  2019-12-18

10.  Increased Myocardial Oxygen Consumption Precedes Contractile Dysfunction in Hypertrophic Cardiomyopathy Caused by Pathogenic TNNT2 Gene Variants.

Authors:  Rahana Y Parbhudayal; Hendrik J Harms; Michelle Michels; Albert C van Rossum; Tjeerd Germans; Jolanda van der Velden
Journal:  J Am Heart Assoc       Date:  2020-04-15       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.